Sanofi buys Kymab in boost to immunotherapy portfolio

12-01-2021

Muireann Bolger

Sanofi buys Kymab in boost to immunotherapy portfolio

nitpicker / Shutterstock.com

Sanofi will buy British immunotherapy firm Kymab for up to $1.45 billion, as it seeks to expand in the rapidly growing immunotherapy field.


Sanofi, Kymab, immunotherapy, Principia Biopharma, Kiadis, KY1005

LSIPR